A Comprehensive Overview of Vision Screening Programmes across 46 Countries

Br Ir Orthopt J. 2022 Jun 10;18(1):27-47. doi: 10.22599/bioj.260. eCollection 2022.

Abstract

Purpose: To describe and compare vision screening programmes and identify variance in number and type of tests used, timing of screening, personnel involved, monitoring and funding to be used as data for optimising, disinvesting or implementing future screening programmes.

Methods: A questionnaire consisting of nine domains: demography & epidemiology, administration & general background, existing screening, coverage & attendance, tests, follow-up & diagnosis, treatment, cost & benefit and adverse effects was completed by Country Representatives (CRs) recruited from 47 countries.

Results: The questionnaire was sufficiently completed for 46 Countries: 42 European countries, China, India, Malawi and Rwanda. Variation of provision was found in; age of screening (0-17 years), tests included (23), types of visual acuity (VA) test used (35 different optotypes), personnel (13), number of screens per child (median 5, range 1-32), and times VA tested (median 3, range 1-30). Infant screening is offered in all countries, whereas childhood vision screening is offered at least once in all countries, but not all regions of each country. All 46 countries provide vision screening between the ages of 3-7 years. Data on screening outcomes for quality assurance was not available from most countries; complete evaluation data was available in 2% of countries, partial data from 43%.

Conclusion: Vision screening is highly variable. Some form of VA testing is being undertaken during childhood. Data collection and sharing should be improved to facilitate comparison and to be able to optimise vision screening programmes between regions and countries.

Keywords: amblyopia; effectiveness; photoscreening; reduced vision; vision screening.

Grants and funding

This project was supported by the European Union’s Horizon 2020 research and innovation programme [grant agreement No 733352]. This study sponsor had no role in the study design, or the collection, analysis and interpretation of the data or in the writing of the report or in the decision to submit the article for publication.